PK 091
Alternative Names: PK-091Latest Information Update: 17 Nov 2023
At a glance
- Originator PharmaKure
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Amyloid beta-protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Neurodegenerative disorders
Most Recent Events
- 22 Sep 2023 Phase-I clinical trials in Neurodegenerative disorders in USA (PO), prior to September 2023 (PharmaKure pipeline, September 2023)